posted on 2021-07-15, 12:34authored byFanwu Gong, Hua-xing Wei, Ji Qi, Huan Ma, Lianxin Liu, Jianping Weng, Xucai Zheng, Qiangsheng Li, Dan Zhao, Haopeng Fang, Liu Liu, Hongliang He, Cuichen Ma, Jinglong Han, Anyuan Sun, Baolong Wang, Tengchuan Jin, Bowei Li, Bofeng Li
The
spread of Coronavirus disease 2019 (COVID-19) is caused by
severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), resulting
in a global pandemic with around four million deaths. Although there
are a variety of nucleic acid-based tests for detecting SARS-CoV-2,
these methods have a relatively high cost and require expensive supporting
equipment. To overcome these limitations and improve the efficiency
of SARS-CoV-2 diagnosis, we developed a microfluidic platform that
collected serum by a pulling-force spinning top and paper-based microfluidic
enzyme-linked immunosorbent assay (ELISA) for quantitative IgA/IgM/IgG
measurements in an instrument-free way. We further validated the paper-based
microfluidic ELISA analysis of SARS-CoV-2 receptor-binding domain
(RBD)-specific IgA/IgM/IgG antibodies from human blood samples as
a good measurement with higher sensitivity compared with traditional
IgM/IgG detection (99.7% vs 95.6%) for early illness onset patients.
In conclusion, we provide an alternative solution for the diagnosis
of SARS-CoV-2 in a portable manner by this smart integration of pulling-force
spinning top and paper-based microfluidic immunoassay.